1. The European Liver Patients Association (April 2005). http://www.elpa-info.org/.
2. Ferlay J. et al. (2010). Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46(4):765–81.
3. European Association for the Study of the Liver http://www.easl.eu
4. Sangiovanni A. et al. (2004). Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology, 126(4): 1005-14.
5. World Health Organisation (2008) ‘WHO Fact Sheet No. 204, Hepatitis B’ Available at: http://www.who.int/mediacentre/factsheets/fs204/en/
6. World Health Organisation (2010) ‘WHO Fact Sheet No. 164, Hepatitis C’ Available at: http://www.who.int/mediacentre/factsheets/fs164/en/
7. Bravi F. et al. (2007). Coffee drinking and hepatocellular carcinoma risk: a meta-analysis. Hepatology, 46:430-435.
8. Larsson S.C. et al. (2007). Coffee consumption and liver cancer: a meta-analysis. Gastroenterology, 132:1740-1745.
9. Bravi F. et al. (2013) Coffee reduces risk for hepatocellular carcinoma: An updated meta-analysis.  Clinical Gastroenterology and Hepatology. (11):1413-1421.
10. Gressner O.A. (2009). About coffee, cappuccino and connective tissue growth factor – or how to protect your liver!? Environmental Toxicology and Pharmacology, 28(1):1-10.
11. Saab S. et al. (2013) Impact of coffee on liver disease a systematic review. Liver International 34(4):495-504.
12. Modi A.A. et al. (2010). Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology, 51: 201-209.
13. Stroffolini T. et al. (2010). Interaction of alcohol intake and cofactors on the risk of cirrhosis. Liver International, 30(6): 867-870.
14. Catalano D. et al. (2010). Protective role of coffee on non-alcoholic fatty liver disease (NAFLD). Digestive Disease and Sciences, 55(11): 3200-3206.
15. Birerdinc A. et al. (2012). Caffeine is protective in patients with non-alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics, 35(1): 76-82.
16. Molloy J.W. et al. (2012). Association of coffee and caffeine consumption with fatty liver disease, non-alcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology, 55(2): 429-36.
17. Gutierrez-Grobe Y. et al. (2012). High coffee intake is associated with lower grade non-alcoholic fatty liver disease: the role of peripheral antioxidant activity. Annals of Hepatology, Volume 11 (3): 350-355.
18. Bambha K. et al. (2013) Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis.  Liver International published online ahead of print: http://www.ncbi.nlm.nih.gov/pubmed/24267865
19. Freedman N.D. et al. (2009). Coffee intake is associated with lower rates of liver disease progression in chronic Hepatits-C. Hepatology, 50: 1360–1369.
20. Costentin C.E. et al. (2011). Association of caffeine intake and histological features of chronic hepatitis C. Journal of Hepatology, Volume 54: 1123-1129.
21. Goh G.B, et al. (2014) Coffee, alcohol, and other beverages in relation to cirrhosis mortality: the Singapore Chinese Health Study.  Hepatology: 60(2):661–669
22. Muriel P. et al. (2010). Coffee and liver disease. Fitoterapia, 81:297-305.
23. Wang G.W. et al. (2009). Anti-hepatitis B virus activity of chlorogenic acid, quinic acid and caffeic acid in vivo and in vitro. Antiviral Research, 83(2):186-90.